๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma

โœ Scribed by Howard I. Scher; Alan Yagoda; Tauseef Ahmed; Daniel Budman; Peter Sordillo; Robin C. Watson

Publisher
Springer
Year
1985
Tongue
English
Weight
214 KB
Volume
14
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II trial of oral 4โ€ฒ demethoxydau
A phase II trial of oral 4โ€ฒ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer
โœ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat

A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
โœ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

Phase II clinical and pharmacological st
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer
โœ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer ๐ŸŒ English โš– 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or

Expanded phase II trial of gemcitabine a
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer
โœ Rachel P. Riechelmann; Carol A. Townsley; Sheray N. Chin; Gregory R. Pond; Jenni ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. A phase 2 trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer led to an objective response in approximately 30% of patients and a median survival of 14 months. In the current study, the authors report further efficacy data of a larger